Patients who did not complete a distress screener were also less likely to receive autologous stem cell transplants.

Clinigen, the global speciality pharmaceutical services group, today announced that Equity Pharmaceuticals, part of the Clinigen Group, has entered into a new collaboration with Servier, an ...

U.S. commercial launch progressing on track with 33 authorized treatment centers as of March 19, 2025, following US FDA approval on November 8, 2024Obe-cel MHRA and EMA marketing authorizations ...

While uncertainty remains in the market, periods of heightened volatility often create compelling opportunities for ...

Takeda has bolstered its near-term pipeline in rare haematological disorders by licensing rights to a polycythaemia vera (PV) treatment being developed by Protagonist Therapeutics. The Japanese ...

A new study published in The Lancet Haematology journal says that an indigenously developed gene therapy for certain blood ...

An indigenously developed gene therapy for specific blood cancers has shown a 73 per cent response rate among patients in ...

This Human Rights Day, DKMS highlights the urgent need for stem cell transplants for South African children battling rare ...

Chugai introduces Lunsumio for intravenous infusion, a bispecific antibody to treat relapsed or refractory follicular lymphoma in Japan: Tokyo Thursday, March 20, 2025, 11:00 Hrs ...

British-Swedish multinational pharmaceutical and biotechnology company AstraZenica on Monday announced the acquisition of ...

India's gene therapy for blood cancers shows 73% response rate, offering hope and cost-effective treatment for patients.

AstraZeneca (AZ) has announced that its immunotherapy Imfinzi (durvalumab) has been approved by the European Commission (EC) ...